Group One Trading’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-20,381
Closed -$968K 8027
2025
Q3
$968K Sell
20,381
-5,336
-21% -$258K ﹤0.01% 3069
2025
Q2
$1.37M Sell
25,717
-4,063
-14% -$185K ﹤0.01% 2476
2025
Q1
$1.21M Buy
+29,780
New +$1.26M ﹤0.01% 2285
2024
Q2
Sell
-2,416
Closed -$51.7K 6643
2024
Q1
$61K Sell
2,416
-35,455
-94% -$852K ﹤0.01% 4545
2023
Q4
$884K Buy
37,871
+12,853
+51% +$253K ﹤0.01% 2563
2023
Q3
$1.27M Sell
25,018
-55,546
-69% -$2.59M ﹤0.01% 2039
2023
Q2
$3.76M Buy
80,564
+80,417
+54,705% +$3.69M 0.01% 1185
2023
Q1
$5.62K Sell
147
-124,481
-100% -$5.55M ﹤0.01% 6230
2022
Q4
$6.83M Buy
124,628
+124,573
+226,496% +$5.34M 0.02% 960
2022
Q3
$2K Sell
55
-745
-93% -$11.4K ﹤0.01% 7103
2022
Q2
$8K Sell
800
-8,600
-91% -$89.7K ﹤0.01% 6857
2022
Q1
$133K Buy
+9,400
New +$165K ﹤0.01% 5215
2021
Q2
Sell
-43,885
Closed -$1.23M 8087
2021
Q1
$1.27M Buy
43,885
+43,819
+66,392% +$1.33M ﹤0.01% 2951
2020
Q4
$2K Hold
66
﹤0.01% 6220
2020
Q3
$2K Sell
66
-2,138
-97% -$74.7K ﹤0.01% 5798
2020
Q2
$55K Sell
2,204
-1,237
-36% -$28.3K ﹤0.01% 4284
2020
Q1
$73K Buy
+3,441
New +$73.8K ﹤0.01% 3501

Other funds holding AKRO

Group One Trading's AKRO Position: Q4 2025 in Review

Group One Trading sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,381 shares — an estimated $968K sold.

Group One Trading first reported a position in AKRO in Q1 2020 and held it in 17 quarters. The position peaked at $6.83M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Group One Trading reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 20,381 Akero Therapeutics shares in Q4 2025, an estimated $968K.
  • Group One Trading first reported a position in Akero Therapeutics in Q1 2020 and held it in 17 quarters.
  • Group One Trading's Akero Therapeutics position peaked at $6.83M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.